Labcorp Holdings Inc. (LH)
Labcorp (LH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Labcorp Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
LH tops Q2 estimates with double-digit EPS growth, margin gains and a raised 2025 outlook, lifting shares pre-market.
Labcorp Holdings (LH) Q2 Earnings and Revenues Top Estimates
Labcorp Holdings (LH) came out with quarterly earnings of $4.35 per share, beating the Zacks Consensus Estimate of $4.14 per share. This compares to earnings of $3.94 per share a year ago.
What Analyst Projections for Key Metrics Reveal About Labcorp (LH) Q2 Earnings
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Labcorp (LH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
Labcorp Q2 Earnings Preview: Diagnostics Strength in Focus
LH is likely to report Q2 growth with diagnostics momentum, key acquisitions, and new biomarker tests bolstering revenue gains.
Will Labcorp (LH) Beat Estimates Again in Its Next Earnings Report?
Labcorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Labcorp Holdings (LH) Earnings Expected to Grow: Should You Buy?
Labcorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Labcorp (LH) a New Buy Stock
Labcorp (LH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Labcorp Upgraded To A Buy As Portfolio Grows And Leverage Stays Low
In my follow-up article on Labcorp, I am upgrading it to a 'Buy' this time. Macro forecasts and the firm's own portfolio growth of solutions and locations could drive more tailwinds to the top line. Leverage risk remains modest in comparison to equity and vs. key peers when considering the D/E and quick ratio.
Labcorp Stock Climbs 25.6% This Year: What's Driving the Surge?
LH stock surges 25.6% this year, powered by specialty testing expansion, key acquisitions and solid financials.
LH Stock Rises Following the Expansion of Precision Oncology Portfolio
Labcorp expands its precision oncology lineup with new cancer tests and a global diagnostic tool.
Why Is Labcorp (LH) Up 2.5% Since Last Earnings Report?
Labcorp (LH) reported earnings 30 days ago. What's next for the stock?
